Fei Liangru, Xu Hongtao
Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital, China Medical University, No.77 Puhe Road, Shenyang North New Area, Shenyang, 110122 Liaoning Province People's Republic of China.
Cell Biosci. 2018 Jul 24;8:43. doi: 10.1186/s13578-018-0242-2. eCollection 2018.
A heterohexameric complex composed of minichromosome maintenance protein 2-7 (MCM2-7), which acts as a key replicative enzyme in eukaryotes, is crucial for initiating DNA synthesis only once per cell cycle. The MCM complex remains inactive through the G1 phase, until the S phase, when it is activated to initiate replication. During the transition from the G1 to S phase, the MCM undergoes multisite phosphorylation, an important change that promotes subsequent assembly of other replisome members. Phosphorylation is crucial for the regulation of MCM activity and function. MCMs can be phosphorylated by multiple kinases and these phosphorylation events are involved not only in DNA replication but also cell cycle progression and checkpoint response. Dysfunctional phosphorylation of MCMs appears to correlate with the occurrence and development of cancers. In this review, we summarize the currently available data regarding the regulatory mechanisms and functional consequences of MCM phosphorylation and seek the probability that protein kinase inhibitor can be used therapeutically to target MCM phosphorylation in cancer.
由微小染色体维持蛋白2 - 7(MCM2 - 7)组成的异源六聚体复合物,作为真核生物中的关键复制酶,对于每个细胞周期仅启动一次DNA合成至关重要。MCM复合物在G1期一直处于无活性状态,直到S期被激活以启动复制。在从G1期到S期的转变过程中,MCM经历多位点磷酸化,这一重要变化促进了其他复制体成员的后续组装。磷酸化对于MCM活性和功能的调节至关重要。MCM可被多种激酶磷酸化,这些磷酸化事件不仅参与DNA复制,还涉及细胞周期进程和检查点反应。MCM的功能失调磷酸化似乎与癌症的发生和发展相关。在本综述中,我们总结了目前关于MCM磷酸化的调控机制和功能后果的可用数据,并探寻蛋白激酶抑制剂可用于治疗性靶向癌症中MCM磷酸化的可能性。